Home/Pipeline/PV-3212

PV-3212

Multiple Sclerosis

Pre-clinicalActive

Key Facts

Indication

Multiple Sclerosis

Phase

Pre-clinical

Status

Active

Company

Provid Pharma

About Provid Pharma

Provid Pharmaceuticals is a private, preclinical-stage biotech developing a first-in-class therapeutic approach for autoimmune diseases by specifically inhibiting disease-associated MHC class II molecules. Its lead program, PV-3212, is a small molecule antagonist of HLA-DRB1*15:01 (DR15), a genetic variant strongly linked to multiple sclerosis, designed to block the autoimmune trigger without broadly suppressing immunity. The company is backed by venture capital, non-profit grants, and NIH funding, leveraging deep medicinal chemistry expertise from its founders. Provid's strategy represents a paradigm shift towards genetically targeted immunomodulation in a large, underserved market.

View full company profile

Therapeutic Areas

Multiple Sclerosis Autoimmune Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
Evobrutinib	EMD Serono	Phase 3	Active